AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has announced changes in the company’s directors and officers. The announcement stated that, on July 14, 2022, the company’s member approved written resolutions of a majority of the members. The resolutions addressed the removal of directors and officer as well as redesignation of some officers and changes in memberships of committees. The announcement noted that the resolutions were approved by 69.29% of the total voting power of the company entitled to vote at a general meeting, which was in accordance with British Virgin Islands law. According to the announcement the proposals outlined several changes, including the following: the removal of Aidong Chen and Sheng Liu as directors along with the removal of Aidong Chen as cochair of the company’s board of directors and co-CEO; that change was effective immediately without compensation for loss of office. Other changes included the redesignation of Chris Chang Yu as company CEO and board chair and the removal of Sheng Liu as chair of the nomination committee of the board and as a member of the compensation committee of the board, with Chris Chang Yu replacing Liu in both positions; these changes are also effective immediately.
To view the full press release, visit https://ibn.fm/b4908
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of March 31, 2022. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer-screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to a report by Frost & Sullivan, AnPac Bio ranked first globally in multicancer screening and detection-test sample volume, accumulative to January 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.